Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

In this Phase 2, single-arm, multicenter clinical trial conducted in the Netherlands, 50 patients with metastatic rectal cancer were treated with 5 days of 5 Gy RT followed by six cycles of intravenous bevacizumab (7.5 mg/kg) and oxaliplatin (130 mg/m<sup>2</sup>) on D1 and capecitabine (1000 mg/m<sup>2</sup>) orally on D1-D14.

A Multimodality Approach to the Initial Management of Stage IV Rectal Cancer